QMSMEDI vs RUBICON: Stock Comparison
QMSMEDI shows a lower P/E and a higher dividend yield, while RUBICON RESEARCH shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
QMSMEDI leads 4; RUBICON leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | QMSMEDI | RUBICON |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | QMSMEDI | RUBICON |
|---|---|---|
| Live Price | ₹138.13 | ₹1,791.1 |
| Day Change | 4.71% | 1.38% |
| Volume | 1.25 L | 1.17 L |
| 52-Week High | ₹140 | ₹1,899 |
| 52-Week Low | ₹98.05 | ₹570.75 |
| Distance from 52W High | -1.34% | -5.68% |
Valuation
| Metric | QMSMEDI | RUBICON |
|---|---|---|
| Market Cap | — | ₹29,632 Cr |
| P/E Ratio | 12.43x | 102.12x |
| P/B Ratio | 1.95x | 22.84x |
| EPS | ₹1.38 | ₹4.99 |
| Book Value | ₹58.93 | ₹77.93 |
| Dividend Yield | 0.38% | 0.08% |
Growth
| Metric | QMSMEDI | RUBICON |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 43.5% |
| EPS Growth (TTM YoY) | 0% | 96.6% |
| Qtr Sales Growth | -7.96% | -19.95% |
| Qtr Profit Growth | -32.43% | -2.75% |
Profitability & Leverage
| Metric | QMSMEDI | RUBICON |
|---|---|---|
| ROE | 10.46% | 19.14% |
| ROCE | 8.9% | 20.49% |
| Net Margin | 0% | 13.48% |
| Operating Margin | 13.3% | 20.68% |
| Debt to Equity | 0.65x | 0.2x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | QMSMEDI | RUBICON |
|---|---|---|
| Promoter Holding | 68.11% | 23.93%▼ 0.04 pp |
| FII Holding | 0% | 7.52%▼ 0.02 pp |
| DII Holding | 1.59% | 9.43%▼ 0.59 pp |
| Public Holding | 30.3% | 23.3%▲ 0.72 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: QMSMEDI and RUBICON RESEARCH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.